Brain Health Education Series
Protecting Your Brain
Alzheimer’s disease is not inevitable. Up to 45% of dementia cases are linked to modifiable risk factors, things you can actually change. This guide covers what we know about brain aging, what the science shows about prevention, and what I think you should be doing right now.
From First Description to First Real Treatments
The story of Alzheimer’s research spans over a century. For most of that time, we could describe the disease but not slow it. That has finally begun to change. Here are the milestones that brought us to where we are today.
Alzheimer Describes the First Case
Dr. Alois Alzheimer presented the case of Auguste Deter, a 51-year-old woman with progressive memory loss, confusion, and paranoia. At autopsy, he found the plaques and tangles that define the disease today. For decades, this was considered a rare condition of younger patients.
Plaques Linked to Dementia Severity
Blessed, Tomlinson, and Roth published the first quantitative evidence that amyloid plaque density in the brain correlated with cognitive decline severity. This began shifting Alzheimer's from a curiosity to a measurable biological disease.
The Cholinergic Deficit Discovered
Peter Davies, David Bowen, and colleagues identified that Alzheimer's brains had dramatically reduced levels of acetylcholine, a key neurotransmitter for memory. This cholinergic hypothesis became the basis for all first-generation Alzheimer's drugs.
Amyloid-Beta Protein Identified
George Glenner and Caine Wong sequenced the amyloid-beta peptide, identifying it as the main component of the plaques Alzheimer had described 78 years earlier. For the first time, researchers had a specific molecular target.
The Nun Study Begins
David Snowdon began studying 678 School Sisters of Notre Dame, revealing that linguistic ability in early life predicted Alzheimer's risk 60 years later. This landmark study introduced the concept of cognitive reserve to a wider audience.
The Amyloid Cascade Hypothesis
John Hardy and Gerald Higgins proposed that amyloid-beta accumulation is the initiating event in Alzheimer's disease, triggering tau tangles, inflammation, and neuronal death. This hypothesis dominated research for the next three decades.
First Alzheimer's Drugs Approved
Donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne) were approved. These cholinesterase inhibitors provide modest symptomatic benefit but do not slow disease progression. They remain the standard of care for symptom management.
PET Imaging Reveals Amyloid in Living Brains
Pittsburgh Compound B (PiB) PET allowed scientists to visualize amyloid plaques in living patients for the first time. This revealed a critical finding: up to 30% of cognitively normal older adults carry significant amyloid burden.
The Glymphatic System Discovered
Maiken Nedergaard's lab discovered a brain-wide waste clearance system that operates primarily during deep sleep, flushing out amyloid-beta and tau through cerebrospinal fluid. This discovery connected sleep quality directly to Alzheimer's risk.
Lancet Commission: 40% of Dementia Is Preventable
The Lancet Commission identified 12 modifiable risk factors collectively responsible for 40% of dementia cases worldwide. This landmark paper shifted the narrative from inevitability to prevention, showing that lifestyle changes could meaningfully reduce risk.
First Anti-Amyloid Drugs Show Efficacy
Lecanemab (Leqembi) slowed cognitive decline by 27% in the CLARITY AD trial. Donanemab (Kisunla) showed 35% slowing in patients with low-to-intermediate tau. After decades of failure, these results proved that clearing amyloid can slow the disease.
Blood Tests and New Frontiers
Blood-based biomarkers (p-tau217) now detect Alzheimer's pathology with over 90% accuracy from a simple blood draw, replacing expensive PET scans. GLP-1 drugs are in Phase 3 trials for neuroprotection. The 2024 Lancet update added vision loss and high LDL cholesterol as modifiable risk factors, raising the preventable fraction above 45%.
Understanding Cognitive Decline
Before talking about prevention, I think it helps to understand what is actually happening in the aging brain. Not all cognitive changes are disease. Knowing the difference between normal aging and something more serious is the first step toward protecting yourself.
14 Modifiable Risk Factors
The 2020 Lancet Commission identified 12 modifiable risk factors responsible for about 40% of worldwide dementia cases. The 2024 update added two more: vision loss and high LDL cholesterol, pushing the preventable fraction above 45%. These are things you can actually change. PAF stands for population-attributable fraction, the percentage of dementia cases that could theoretically be prevented by eliminating that risk factor.
Less Education
Lower educational attainment reduces cognitive reserve. Each year of education provides about a 7% reduction in dementia risk by building denser neural networks and more efficient cognitive strategies.
Hearing Loss
The single largest modifiable risk factor. Hearing loss leads to social withdrawal, reduced stimulation, and accelerated brain atrophy. A 25 dB hearing loss equals 7 years of cognitive aging. The ACHIEVE trial showed hearing aids can slow cognitive decline by 48%.
Traumatic Brain Injury
Moderate-to-severe TBI increases dementia risk 2 to 4 fold. Repetitive mild TBI from contact sports is linked to chronic traumatic encephalopathy. Wear your seatbelt and helmet.
Hypertension
Midlife hypertension damages small brain arteries, causes white matter disease, and reduces cerebral blood flow. The SPRINT MIND trial showed that getting systolic blood pressure below 120 reduced MCI risk by 19%.
Excessive Alcohol
More than 21 units per week increases dementia risk through direct brain toxicity, thiamine deficiency, and increased fall risk. The idea that light drinking protects the brain has weakened with newer research.
Obesity
Midlife obesity increases dementia risk through insulin resistance, chronic inflammation, and vascular disease. Managing weight in your 40s and 50s is an investment in brain health decades later.
High LDL Cholesterol
Added by the 2024 Lancet Commission update. ApoB-containing lipoproteins contribute to cerebral atherosclerosis, reduce brain blood flow, and may directly promote amyloid accumulation. Lowering LDL protects your brain, not just your heart.
Smoking
Current smoking increases dementia risk by 30 to 50% through oxidative stress, vascular damage, and promotion of amyloid buildup. Former smokers who quit for 10+ years approach never-smoker risk levels.
Depression
Late-life depression increases dementia risk by 65%. Chronic depression elevates cortisol, which is directly toxic to hippocampal neurons. Depression is both a risk factor for dementia and sometimes an early symptom of it. It is treatable.
Social Isolation
Loneliness increases dementia risk by about 40%, independent of depression. People with 5 or more close social contacts have approximately 26% lower dementia risk. Social engagement is cognitive exercise.
Physical Inactivity
Sedentary behavior reduces brain blood flow, lowers BDNF, increases insulin resistance, and impairs the glymphatic system's ability to clear waste. Even replacing 30 minutes of sitting with walking makes a measurable difference.
Air Pollution
Fine particulate matter (PM2.5) crosses the blood-brain barrier and drives neuroinflammation. This risk factor is especially significant in urban environments and developing countries.
Diabetes
Type 2 diabetes increases dementia risk by 50 to 100%. Insulin resistance in the brain impairs amyloid clearance and promotes tau formation. Even prediabetes is associated with subtle cognitive changes.
Vision Loss
Added by the 2024 Lancet Commission update. Uncorrected vision loss reduces environmental stimulation, increases social isolation, and accelerates cognitive decline. Cataract surgery has been linked to reduced dementia risk.
The bottom line
You do not need to address all 14 risk factors perfectly. But the more of these you manage, the more you are stacking the odds in your favor. The same interventions that protect your heart, your hearing, and your mood are simultaneously protecting your brain. This is not theoretical. The data are strong.
What You Can Do
I want to be practical here. The evidence supports specific interventions, and I have ranked them by the strength of that evidence. You do not need to do everything perfectly. Start with what is most actionable for you and build from there. Every intervention you adopt stacks with the others.
The Blood-Brain Barrier and Inflammation
Your brain is not isolated from the rest of your body. A specialized barrier protects it, but when that barrier breaks down, inflammation from your blood vessels, your gut, and even your mouth can reach your brain. Understanding this connection changes how you think about brain protection.
Current and Emerging Treatments
After decades of failure, we finally have treatments that can slow Alzheimer’s disease, not just manage symptoms. We also have diagnostic tools that were unimaginable five years ago. Here is what I think you should know about the current landscape, with both the promise and the honest limitations.
Important context
The anti-amyloid drugs represent real scientific progress. They prove that clearing amyloid can slow the disease. But the effect sizes are modest, the side effects require careful monitoring, and these treatments only work in early-stage disease. Prevention through lifestyle modification remains the most impactful strategy for most people.
Lecanemab (Leqembi)
The first anti-amyloid antibody to show clear clinical benefit. It targets soluble amyloid protofibrils, the most toxic form of amyloid, and is given as an IV infusion every 2 weeks or by subcutaneous injection at home.
Key findings
- Slowed cognitive decline by 27% over 18 months in the CLARITY AD trial (1,795 participants with early Alzheimer's)
- Cleared 59 centiloids of amyloid on PET imaging, representing substantial plaque removal
- Subcutaneous self-injection formulation approved in 2025 for at-home use, reducing infusion burden
- Costs approximately $26,500 per year; covered by Medicare with evidence development requirements
Limitations
- ARIA (amyloid-related imaging abnormalities): brain swelling in 12.6% and microhemorrhages in 17.3% of patients
- ApoE4 homozygotes at highest risk (about 36% ARIA rate); requires MRI monitoring
- Absolute effect size is modest: a difference of 0.45 points on an 18-point scale
- Only approved for early Alzheimer's (MCI or mild dementia with confirmed amyloid)
Donanemab (Kisunla)
Targets deposited amyloid plaques and is designed as a time-limited treatment. Once amyloid is cleared below a threshold, treatment stops. This 'treat-to-target' approach could reduce long-term cost and side effect exposure.
Key findings
- Slowed cognitive decline by 35% in patients with low-to-intermediate tau burden (the best responders)
- About 47% of patients achieved amyloid clearance by 12 months and were switched to placebo
- Given as a monthly IV infusion (less frequent than lecanemab's every-2-week schedule)
- Total treatment cost may be lower than lecanemab due to the time-limited design
Limitations
- Higher ARIA rate than lecanemab: brain swelling in 24%, microhemorrhages in 31.4%
- Three deaths in the treatment group, two considered treatment-related
- Less benefit in patients with high tau burden, suggesting treatment works best when started early
- Costs approximately $32,000 per year during active treatment
Blood Biomarkers (p-tau217)
Blood-based biomarkers have transformed Alzheimer's diagnosis. A simple blood draw can now detect Alzheimer's pathology with over 90% accuracy, replacing expensive PET scans and invasive spinal taps for many patients.
Key findings
- p-tau217 is the most accurate single blood biomarker: 92 to 96% sensitivity and 88 to 95% specificity for amyloid-positive status
- When combined with amyloid-beta 42/40 ratio, diagnostic accuracy exceeds 95%
- Available through multiple platforms (Roche Elecsys, Fujirebio Lumipulse, C2N PrecivityAD2)
- Enables earlier diagnosis in primary care settings without specialist referral for initial testing
Limitations
- Amyloid positivity does not guarantee symptoms will develop; up to 30% of normal older adults are amyloid-positive
- Requires careful pre-test counseling about what results mean and do not mean
- Not yet recommended for routine screening in asymptomatic populations
- Insurance coverage varies; out-of-pocket cost can be $500 to $1,200
GLP-1 Drugs and Neuroprotection
GLP-1 receptor agonists like semaglutide, originally developed for diabetes and obesity, are generating major excitement as potential neuroprotective agents. GLP-1 receptors are expressed throughout the brain, particularly in the hippocampus and cortex.
Key findings
- Large observational studies show GLP-1 users have 40 to 70% lower rates of dementia diagnosis
- GLP-1 agonists reduce neuroinflammation, improve brain insulin signaling, enhance synaptic plasticity, and reduce amyloid production in animal models
- EVOKE and EVOKE+ trials (Novo Nordisk): Phase 3 trials of oral semaglutide in early Alzheimer's with about 3,700 participants; results expected 2027 to 2028
- If positive, GLP-1 drugs could represent a paradigm shift: an oral, well-tolerated, widely available treatment with both metabolic and brain benefits
Limitations
- All human evidence so far is observational and subject to confounding (healthier patients may be more likely to receive newer drugs)
- Randomized trial results will not be available until 2027 to 2028
- Not currently approved or recommended for brain health indications
- The neuroprotective dose may differ from the metabolic dose
I find the GLP-1 neuroprotection data genuinely exciting. But I want to be honest: we do not have randomized trial evidence yet. The observational data are compelling, and the biological rationale is strong. We will know a lot more in the next 2 to 3 years.